Bottom line
RYCFX vs BBH: the short answer
RYCFX (Biotechnology Fund) and BBH (VanEck Biotech ETF) are both mutual funds.
But RYCFX is far broader, holding 74 positions to 25 for BBH, so beyond the top names it adds exposure BBH doesn't have.
BBH is cheaper at 0.35% vs 2.38% — a difference of $203 a year per $10,000 invested.
Over five years, RYCFX returned +3.0% a year vs +2.7% for BBH.
Updated Nov 19, 2026
RYCFX vs BBH side by side
| RYCFX | BBH | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | Guggenheim | VanEck |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 2.38% | 0.35% |
| Annual cost per $10k | $238 | $35 |
| 10-yr cost on $10k (prospectus) | $2,763 | $443 |
| Max front load | 0% | None |
| 12b-1 fee | 1% | — |
| 1-yr return | +28.4% | +21.2% |
| 5-yr return (annualized) | +3.0% | +2.7% |
| 10-yr return (annualized) | +4.8% | +4.5% |
| Best quarter | +28.0% | +27.6% |
| Worst quarter | −22.7% | −18.2% |
| Net assets (fund) | $136.8M | $395.6M |
| Number of holdings | 74 | 25 |
| Portfolio turnover | 75% | 19% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | RYCFX | BBH | Difference |
|---|---|---|---|
| 2025 | +29.4% | +21.2% | +8.3% |
| 2024 | −1.7% | −4.4% | +2.7% |
| 2023 | +5.0% | +3.9% | +1.1% |
| 2022 | −13.9% | −15.1% | +1.2% |
| 2021 | +0.8% | +11.8% | −11.0% |
| 2020 | +20.9% | +22.1% | −1.2% |
| 2019 | +23.8% | +25.8% | −2.0% |
| 2018 | −9.9% | −10.2% | +0.3% |
| 2017 | +28.4% | +16.6% | +11.8% |
| 2016 | −20.3% | −15.0% | −5.3% |
Source: Fund prospectus bar charts
Holdings overlap
16 of RYCFX's top 25 holdings also appear in BBH's top 25.
| Holding | RYCFX | BBH |
|---|---|---|
| Amgen Inc | 5.05% | 15.25% |
| Gilead Sciences Inc | 4.49% | 12.79% |
| Vertex Pharmaceuticals Inc | 4.32% | 9.10% |
| Regeneron Pharmaceuticals Inc | 2.93% | 6.21% |
| Revolution Medicines Inc | 2.48% | 5.27% |
| Alnylam Pharmaceuticals Inc | 2.36% | 3.83% |
| Beone Medicines Ltd | 2.17% | 2.81% |
| Moderna Inc | 2.15% | 3.36% |
| Biogen Inc | 2.13% | 3.63% |
| Natera Inc | 2.12% | 4.92% |
| Illumina Inc | 1.94% | 3.17% |
| Insmed Inc | 1.79% | 2.67% |
| United Therapeutics Corp | 1.72% | 2.83% |
| Incyte Corp | 1.62% | 2.49% |
| Neurocrine Biosciences Inc | 1.52% | 2.08% |
Source: SEC Form N-PORT
RYCFX top 10
- Abbvie Inc — 8.17%
- Amgen Inc — 5.05%
- Gilead Sciences Inc — 4.49%
- Vertex Pharmaceuticals Inc — 4.32%
- Regeneron Pharmaceuticals Inc — 2.93%
- Revolution Medicines Inc — 2.48%
- Alnylam Pharmaceuticals Inc — 2.36%
- Beone Medicines Ltd — 2.17%
- Moderna Inc — 2.15%
- Biogen Inc — 2.13%
BBH top 10
- Amgen Inc — 15.25%
- Gilead Sciences Inc — 12.79%
- Vertex Pharmaceuticals Inc — 9.10%
- Regeneron Pharmaceuticals Inc — 6.21%
- Revolution Medicines Inc — 5.27%
- Argenx SE — 4.97%
- Natera Inc — 4.92%
- IQVIA Holdings Inc — 4.31%
- Alnylam Pharmaceuticals Inc — 3.83%
- Biogen Inc — 3.63%
FAQ
What is the difference between RYCFX and BBH?
Which is cheaper, RYCFX or BBH?
Should I own both RYCFX and BBH?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.